PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 1534: OriC613: A novel therapeutic strategy for gastric and pancreatic cancers utilizing dual-targeting CAR-T cells against MSLN and CLDN18.2 with a favorable safety profile and potent efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

XHX. HeSYShasha YangHGHao Guo

Discussion

Loading...

Member takes

Overview

Preclinical findings show that OriC613 enhances tumor selectivity in gastric and pancreatic cancers, suggesting a promising therapeutic strategy.

Key Points

  • This research aims to develop a dual-targeting CAR-T cell therapy to enhance treatment efficacy for gastric and pancreatic cancers.
  • Developed OriC613, a dual-targeting CAR-T cell based on AND-logic gate.
  • Engineered high-affinity anti-CLDN18.2 scFv combined with moderate-affinity anti-MSLN VHH.
  • Evaluated safety and efficacy in preclinical gastric and pancreatic cancer models.
  • OriC613 showed no cytotoxic activity against normal gastric models.
  • Demonstrated enhanced potency against dual-positive tumors compared to conventional CAR-T cells.
  • Significant tumor regression observed in high-burden gastric models with sustained T-cell persistence.

Cite This Study

He et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd62a79560c99a0a36c9https://doi.org/10.1158/1538-7445.am2026-1534
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract A089: Improving Therapeutic Window of Claudin 18.2-Targeted CAR-T cells in Pancreatic Cancer2025
  2. 2Abstract 140: Allogeneic CAR-iNKT cell therapy targeting CLDN18.2-positive gastric and pancreatic cancers.2026
  3. 3Abstract 6316: Exploring the resistant mechanism of CAR T cell therapy targeting CLDN18.2 by single-cell sequencing2024
  4. 4Abstract 1435: Utilization of CLDN18.2 syngeneic mouse models to study chimeric antigen receptor T cells in immunocompetent mice2024 · 1 citations
  5. 5Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer2024 · 37 citations